4597.T Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 apr 2024 @ 08:15):

Stats
Dagens volum	954 300
Gjennomsnittsvolum	3.29M
Markedsverdi	5.01B
EPS	¥0 ( 2024-02-14 )
Neste inntjeningsdato	( ¥0 ) 2024-05-12
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-3.93
ATR14	¥0.159 (0.61%)

Volum Korrelasjon

Lang: 0.13 (neutral)

Kort: -0.22 (neutral)

Signal:(48.14) Neutral

Solasia Pharma K.K. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Solasia Pharma K.K. Korrelasjon - Valuta/Råvare

-0.08
( neutral )

0.15
( neutral )

0.31
( neutral )

0.16
( neutral )

-0.34
( neutral )

-0.09
( neutral )

Solasia Pharma K.K. Økonomi

Annual	2023
Omsetning:	¥617.00M
Bruttogevinst:	¥-163.00M (-26.42 %)
EPS:	¥-6.61

FY	2023
Omsetning:	¥617.00M
Bruttogevinst:	¥-163.00M (-26.42 %)
EPS:	¥-6.61

FY	2022
Omsetning:	¥1.09B
Bruttogevinst:	¥662.00M (60.62 %)
EPS:	¥-16.76

FY	2021
Omsetning:	¥559.00M
Bruttogevinst:	¥374.00M (66.91 %)
EPS:	¥-19.04

Financial Reports:

No articles found.

Solasia Pharma K.K.

Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.